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Background: The evasion of cell death is one of the hallmarks of cancer, contributing to both tumor progression and
resistance to therapy. Dedifferentiated and anaplastic thyroid carcinomas that do not take up radioiodine are resistant
to conventional anticancer treatments and patients with these tumors are difficult to treat. BH3 mimetics are a new
class of drugs that target anti-apoptotic proteins of the BCL-2 family and promote cell death. The purpose of this study
was to analyze the molecular effects of the BH3 mimetic GX15-070 on thyroid carcinoma cell lines and to characterize
cell death induced by GX15-070.
Methods: A total of 17 cell lines derived from follicular, papillary, and anaplastic thyroid carcinomas were treated with
GX15-070. Cell viability was measured with MTT assay while cell cycle phase distribution and subG1 peaks were determined
after propidium iodide staining. We assessed cell death via the caspase 3/7 activity, caspase cleavage products, lactate
dehydrogenase (LDH) liberation assays, and a LC3 analysis by western blot. Ultrastructural changes were analysed by
electron microscopy of GX15-070-treated cells.
Results: After GX15-070 treatment, the number of viable cells was decreased in all cell lines examined, with IC50 values
ranging from 48nM to 3.25 μM. We observed biochemical markers of autophagic cell death and necrosis like LC3
conversion and LDH release after the GX15-070 treatment. Electron microscopy revealed several common characteristic
ultrastructural changes like swelling of mitochondria, dilatation of rough endoplasmic reticulum, membrane blebbing and
formation of vacuoles. GX15-070 treatment induced DNA fragmentation detected by subG1-peak induction and an arrest
in G1 phase of the cell cycle. Caspase activation after GX15-070 incubation was detected but had no effect on viability
of cells.
Conclusions: With these experiments we demonstrated the efficacy of the BH3 mimetic drug GX15-070 acting against
dedifferentiated thyroid carcinoma cells of various histological origins by the induction of cell death. GX15-070-treated
cells underwent non-classical cell death with signs of apoptosis, autophagy and necrosis in parallel. GX15-07 and related
compounds thus may be a new therapeutic option for dedifferentiated thyroid carcinoma of various histological subtypes.
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Thyroid carcinoma is the most frequently diagnosed ma-
lignant tumor of endocrine organs [1, 2]. Most of thyroid
carcinomas (approx. 95 to 97 %) are derived from follicu-
lar epithelial cells of the thyroid gland [3, 4]. They are
grouped according to pathological criteria into well-* Correspondence: martina.broecker@uni-due.de
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(approx. 10 %) subtypes. Only about 10 % of thyroid car-
cinomas are initially classified as poorly differentiated or
undifferentiated, anaplastic subtypes [3, 4]. While most
patients with differentiated papillary thyroid carcinoma
(PTC) or follicular thyroid carcinoma (FTC) are success-
fully treated with surgery and a subsequent radioiodine
treatment to destroy residual tumor cells, in a subgroup of
these patients the disease recurs even under TSH suppres-
sive therapy [2, 5]. These patients have different outcomes
due to the degree of dedifferentiation of their tumors andAccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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tiated and anaplastic thyroid carcinomas (ATC) on the other
hand have lost the ability to take up radioiodine and are
highly aggressive and lethal tumors [7, 8]. Due to the lack of
sufficient radioiodine uptake and the aggressive growth
pattern, ATCs and dedifferentiated thyroid carcinomas are
difficult to treat and have a bad prognosis. In addition to
surgery and therapeutic radioiodine treatment, chemo-
therapy is another therapeutic option for patients with
radioiodine-refractory thyroid carcinoma but is less effect-
ive with partial response rates of only 25 % or less [9–11].
Cancer cells are characterized by an imbalance between
cell division and cell death pathways. This imbalance is
caused by an evasion of growth suppressors and sustained
proliferative signaling on the one hand and resistance to
cell death on the other hand. In addition to further char-
acteristics, it contributes to the “hallmark of cancer cells”
[12]. Cell death can be propagated by various pathways
that are regulated by different intracellular signaling cas-
cades, i.e. mainly apoptosis, necrosis, necroptosis, and au-
tophagy [Review: 13].
Apoptosis is a form of regulated cell death characterized
by the activation of a family of cysteine protease, the cas-
pases [14]. Following caspase activation, characteristic mor-
phological changes are depicted by apoptotic cells like
condensation of chromatin and DNA fragmentation, mem-
brane blebbing and disintegration of the cells into small
fragments called apoptotic bodies [15, 16]. Apoptosis is me-
diated by two signalling pathways, which regulate type 1
and type 2 of apoptosis, the extrinsic (type 1) and the in-
trinsic (type 2) pathway [17]. The intrinsic pathway is trig-
gered by intracellular signals like oxidative stress or damage
of DNA. It is regulated by members of the B-cell lymphoma
2 (BCL-2) family of proteins that contains pro- and anti-
apoptotic members that are characterized by the presence
of sequence motifs termed BCL2 homology domains (BH
domains) [18, 19]. The pro-apoptotic proteins BAK and
BAX directly execute apoptosis by dimerization and forma-
tion of pores in the outer membrane of mitochondria. In
turn, cytochrome c and other apoptotic factors are released
from the mitochondrial intermembrane space and the exe-
cutioner caspases 3, 6 and 7 are activated [17]. BAX and
BAK proteins are regulated by anti-apoptotic proteins like
BCL-2, BCL-xL and MCL-1 which inhibit BAX and BAK
by binding. The extrinsic pathway on the other hand is acti-
vated after external activation of death receptors on the cell
surface (tumor necrosis factor receptor 1, Fas, TRAIL re-
ceptor 1 and 2 [20] which in turn activate executioner cas-
pases 3, 6 and 7 [21].
Cell death by necrosis on the other hand is defined by
early plasma membrane permeabilisation and cell swelling
followed by cell rupture and release of cellular mate
rial. In contrast to apoptosis, the cell nuclei in necr-
osis remain largely intact [Review:22]. Biochemically,lysosomal hydroxylases are often released during necro-
sis and help in the breakdown of the cell [23]. Necrosis
originally was defined as an unregulated form of cell
death in answer to severe insults of the cell. It now has
become clear that necrosis also can occur in a regulated
manner which is called necroptosis and is dependent
on activation of specific signalling molecules like
receptor-interacting protein 1 (RIP1) [22, 24].
Autophagy as another form of cell death describes the
process of digesting the cell´s own cellular components
Review: [25]. Macroautophagy, which is mostly referred to
as autophagy, is a cellular process of degrading and recyc-
ling of organelles and cell components [26]. Autophagy is a
regulated cellular process that begins with the formation of
a phagophore which develops into a double-membrane-
encoded vesicle, the autophagosome [27]. The autophago-
some contains cellular components that are degraded by
acidic hydrolases after fusion with a lysosome, a process
called autolysosome formation [28].
Tumor formation is commonly regarded as diminished
cell death that occurs in cells carrying genetic alterations
that enable their uncontrolled proliferation. Furthermore,
success of cytotoxic tumor and radiation therapies depends
on the activation of cell death pathways since cytotoxic
agents eliminate tumor cells mainly by inducing apoptotic
cell death [29, 30]. The expression of the anti-apoptotic
proteins BCL-2, BCL-xL, and MCL-1 is upregulated in
many cancer types and these proteins, as pro-survival onco-
genes, contribute to the uncontrolled proliferation [31].
Furthermore, an important function of members of the
BCL-2 family in resistance to classical tumor therapeutics
such as chemotherapy has been shown [Review: 32]. There-
fore, anti-apoptotic proteins of the BCL-2 family are inter-
esting targets for a therapeutic inhibition to facilitate
apoptosis induction in cancer cells.
BH3 mimetics are a new class of low molecular cancer
therapeutics which inhibit anti-apoptotic members of the
BCL-2 family by mimicking the binding of BH3-only pro-
teins to the hydrophobic groove of anti-apoptotic proteins
[33]. In turn, heterodimerization with pro-apoptotic pro-
teins is prevented and pro-apoptotic proteins can assem-
ble to trigger cell death [34]. One of these BH3 mimetic
compounds is GX15-070 (Obatoclax) of which Nguyen
et al. [35] demonstrated a binding to all anti-apoptotic
BCL-2 proteins inhibiting ligation of pro-apoptotic pro-
teins to their hydrophilic groove. GX15-070 showed po-
tent inhibition of a number of cell lines from different
tumors but was less effective in normal cells, which makes
GX15-070 and related compounds good candidates for
anticancer therapeutics [36–40].
Based on the importance of BCL-2 proteins for un-
controlled proliferation and therapy resistance of malig-
nant tumor cells, we studied the effect of the BH3
mimetic GX15-070 on a panel of 17 thyroid carcinoma
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GX15-070 in this cell model since BH3 mimetics are a
potential new therapeutic option for dedifferentiated
thyroid carcinomas. The effect of GX15-070 on cell pro-
liferation and cell death induction was studied. The type
of cell death induced by GX15-070 was characterized by
biochemical methods and by transmission electron mi-
croscopy. Expression patterns of various proteins of the
BCL-2 family were compared with different sensitivities
of the cell lines towards GX15-070.
Methods
Compounds and antibodies
GX15-070 (Obatoclax) was obtained from Enzo Life
Sciences (Farmingdale, NY, USA). It was dissolved in
DMSO to 10 mM, stored in aliquots at -20 °C and fur-
ther diluted in the appropriate medium. Antibodies
were from Cell Signaling Technology (Danvers, MA,
USA), the pan-caspase inhibitor N-(2-Quinolyl)valyl-
aspartyl-(2,6-difluorophenoxy)methyl Ketone (Q-VD-
OPh) was purchased from Merck Millipore (Darmstadt,
Germany) and staurosporine was from Selleck Chemi-
cals (Houston, TX, USA).
Cell lines and cell culture
In this study we used cell lines derived from different
thyroid cancer subtypes: SW1736, HTh7, HTh74,
HTh83, C643, 8305 and 8505C were descended from
ATC. BHT101, B-CPAP, K1 and TPC1 originated from
PTC. ML1, RO82W, and TT2609 are FTC cell lines.
FTC133, FTC236, and FTC238 are derived from a FTC
and its metastases from the same patient, with FTC133
originating from the primary tumor, FTC236 from a
lymph node metastasis, and FTC238, being derived from
a lung metastasis. The HTh7 [41], HTh74 [42], HTh83
[43], C643 [44], and SW1736 [45] cell lines were a gift
from Prof. Heldin (Uppsala, Sweden), all other cell lines
and Jurkat leukemia cells that were used as controls,
were purchased from ATCC (Manassas, Virginia, USA),
ECACC (Salisbury, UK) and DSMZ (Braunschweig,
Germany). They were grown in their appropriate media
supplemented with 10 % fetal bovine serum (FBS; Life
Technologies, Paisley, PA, USA) at 37 °C at 5 % CO2.
Viability testing of cells
Depending on the cell line 1 to 5 x 104 cells were seeded
into each well of a 96 well plate within their normal growth
medium. Medium was replaced after 24 h with medium
without FBS containing 0.1 % bovine serum albumin
(BSA), and the concentrations of GX15-070, Q-VD-OPh or
a combination of GX15-070 and Q-VD-OPh were added as
indicated. After 48 h, viable cells were stained with the Cell
Titer Aqueous One Solution MTT assay for two to three
hours (Promega, Madison, WI, USA) and optical densitywas measured at 490 nm using an Emax microplate pho-
tometer (Molecular Devices, Sunnyvale, CA, USA). Control
values without treatment were performed as 18-fold deter-
minations, while all concentrations of GX15-070 and com-
binations were tested in 8-fold. Each experiment was
performed at least three times. Calculation of results and
Student’s t-tests were performed using SoftMax® pro soft-
ware (Molecular Devices, Sunnyvale, CA, USA). IC50
values (drug concentration that caused a 50 % reduction in
MTT assay) were calculated with four parameter logistic
function dose–response curves using Sigma Plot™ software
(Systat, San Jose, CA, USA).
Determination of lactate dehydrogenase (LDH) release
and caspase 3/7 activity measurement
To measure the release of LDH from damaged cells, the
CytoTox-ONE homogeneous membrane integrity assay
(Promega, Madison, WI, USA) was used. The Apo-ONE
homogeneous Caspase-3/7 assay served to measure the
activity of caspases 3 and 7 (Promega, Madison, WI,
USA). In short, we seeded and grew the cells as described
under “viability testing of cells”, with the only difference
that black 96 well plates with a clear bottom were used.
On day two, medium was replaced by 100 μl medium
with 0.1 % BSA containing the indicated GX15-070 con-
centrations. After the indicated times 50 μl of medium
from each well was transferred to a second 96 well plate
and equilibrated to 20 °C. According to the instructions
of the manufacturer, 50 μl of CytoTox reagent were
added followed by incubation at room temperature (RT)
in the dark for 10 min. After adding 25 μl of stop solu-
tion, fluorescence was determined with excitation and
emission wavelengths of 560 nm and 590 nm, respect-
ively. In each experiment, controls without cells and fully
lysed cells as maximum LDH release controls were in-
cluded. By adding 50 μl of Apo-ONE reagent containing
a fluorometric substrate, cell lysis reagent, and buffer, we
determined caspase 3 and 7 activity in GX15-070-treated
cells in the original stimulation plate. Sixty minutes later,
after excitation with 499 nm, fluorescence was measured
at 521 nm (emission). All values were determined 8-fold
and repeated at least two times. We calculated the results
and performed Student’s t-test using SoftMax® pro soft-
ware (Molecular Devices). For positive control of apop-
tosis induction [46], Jurkat cells were harvested by
centrifugation, resuspended in medium with 0.1 % BSA,
seeded and staurosporine or staurosporine and Q-VD-
OPh were added. On day 2, the 96 well plate was centri-
fugated, 50 μl of supernatant was discarded and ApoONE
assay was performed as described.
Cell cycle analysis
Cells were seeded in six well plates (1 to 5 x 105 cells
per well, depending on the cell line) in their appropriate
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without FBS containing 0.1 % BSA and 0.1 μM GX15-
070 was added for 24 h. Cells were harvested and fixed
in ice-cold 70 % ethanol. After adding RNase A (60 μg/
ml) and propidium iodide (25 μg/ml) in PBS, samples
were incubated for 20 min at RT in the dark. Samples
were measured with a FACS Calibur flow cytometer
(Becton Dickinson, San Jose, CA) and cell cycle stages
were analyzed using ModFit LT™ Software (Verity Soft-
ware House, Topsham, ME, USA).
Cell stimulation and protein extraction
For ELISA and western blot analyses, cells were seeded on
cell culture dishes (15 cm diameter) and grown for one to
two days until they reached 80 to 85 % confluence. Full
medium was replaced with medium containing 0.1 % BSA
and cells were maintained in this medium for one hour
before adding 0.1 μM GX15-070. For controls, Jurkat cells
were centrifugated, resuspended in medium containing
0.1 % BSA and treated with staurosporine or a combin-
ation of staurosporine and Q-VD-OPh. After the treat-
ment times indicated, medium was removed and cells
were washed with ice-cold PBS. All further steps were per-
formed on ice. Cell lysis was conducted in lysis buffer con-
taining protease and phosphatase inhibitors (Complete
protease inhibitor and phosStop phosphatase inhibitor,
Roche Applied Science, Mannheim, Germany). The vehicle-
stimulated control cells were maintained for 24 h in
medium containing BSA before lysis. Lysates were clarified
by centrifugation at 10,000 × g for 10 min at 4 °C. Protein
concentration was determined with a modified Bradford
assay (Bio-Rad Laboratories, Hercules, CA, USA).
Cleaved caspase ELISA
Semi-quantitative determination of cleaved caspase 3
(Asp175) as a marker of apoptosis induction was per-
formed by using a specific sandwich ELISA for this
cleaved protein (Cell Signaling Technologies). In brief,
cells were plated, stimulated, and lysed as described above.
Diluted cell lysate (100 μl) containing 100 μg of total cell
protein were incubated in each of the antibody-coated
wells of the plate at 4 °C overnight. All values were deter-
mined four-fold and repeated at least once. After washing,
detection was performed by use of an antibody specific for
the cleaved protein and a horseradish peroxidase-labelled
secondary antibody. TMB substrate reaction was stopped
after 30 min at RT and absorbance was determined at
450 nm (EMax microplate reader, Molecular Devices). Re-
sults were calculated as percentages of the unstimulated
controls using SoftMax® pro software (Molecular Devices).
Western blot analyses
Western blot analyses were performed to analyze the ex-
pression of the BCL-2 family protein members and theeffects of GX15-070 on LC3 cleavage. Total protein
(30 μg) from untreated or vehicle-treated and GX15-070-
treated cells (see above) were denatured by boiling in SDS
sample buffer for 5 min. Proteins were separated by means
of SDS-PAGE on stain-free polyacryl amide gels (Bio-Rad
Laboratories) to enable loading control. After electrophor-
esis, optical densities of stained proteins in each lane were
documented and verified with a CCD camera system and
the Quantity One® software, respectively (both Bio-Rad
Laboratories). When integrated optical densities of pro-
teins in each lane did not differ more than maximal 10 %,
proteins were transferred to a nitrocellulose membrane
(Bio-Rad Laboratories). After blocking with BSA, the blots
were incubated overnight at 4 °C with the appropriate pri-
mary antibody (Cell Signaling Technologies) in TBS buffer
containing 0.1 % Triton X100. After washing, an appropri-
ate secondary antibody coupled to horseradish peroxidase
was added. Detection of bound antigens was performed
with an enhanced chemiluminescence detection kit
(Amersham ECL Advance, GE Healthcare, Piscataway, NJ,
USA). Using a CCD-camera system (Bio-Rad Laborator-
ies), the signal intensities were evaluated.
Electron microscopy
Cells were plated and treated as described above. Cell cul-
ture supernatant was collected together with the scraped
cells and centrifuged. The cell pellets were fixed in a solu-
tion of 2.5 % glutaraldehyde in 0.1 M sodium cacodylate
buffer (pH 7.4; RT) for 90 min followed by washing in so-
dium cacodylate buffer (3 x 20 min). After osmification
with 1 % osmiumtetroxide in cacodylate buffer for
120 min the cells were washed again. Then aqueous etha-
nol solutions were applied (30 %–50 %–70 %) followed by
70 % ethanol containing 1 % of uranyl acetate for 60 min.
After this procedure, 80 %, 90 %, and 96 % ethanol
(45 min each) and absolute ethanol (3 x 15 min each) was
applied. After this we administered propylenoxide (2 x
20 min) followed by EPON™ solutions in propylenoxide
with increasing EPON™ concentrations (propylenoxide :
EPON™ = 3:1, 1:1, 1:3; 60 min each) and finally pure
EPON™ overnight at RT. For the polymerization a heated
storage device (60 °C, two days) was used. After trimming
solid EPON™ blocs were cut on a Reichert-Jung Ultracut
E®-ultramicrotome, which had been set to a thickness of
60 nm. Sections were then mounted on 200 Mesh hex-
agonal copper grids and treated for 6 min with 1 % aque-
ous uranyl acetate solution before exposing them for three
minutes to lead citrate (0.4 %) for contrast enhancement.
A Zeiss transmission electron microscope (EM902A) was
used for investigation at 80KV applying magnifications
ranging from 2,500 to 145,000×. Digital image acquisition
was performed with a Morada slow-scan-CCD camera
connected to a PC running ITEM® 5.0 software (both
Olympus Soft-imaging-systems, Münster, Germany).
Table 1 Cell line origin, doubling times and IC50 values of all
thyroid carcinoma cell lines examined after 48 h of GX15-070
treatment (MTT assay), mean of three independent experiments
Cell line Origin IC50 GX15070 (μM) Doubling time (h)
FTC133 FTC 0.052 42
FTC236 FTC 0.089 37
FTC238 FTC 0.048 30
ML1 FTC 0.16 68
TT2609 FTC 0.62 52
RO82W FTC 1.12 48
BHT101 PTC 0.072 46
B-CPAP PTC 0.15 36
TPC-1 PTC 0.21 30
K1 PTC 3.25 38
SW1736 ATC 0.11 37
C643 ATC 0.049 31
HTh7 ATC 0.078 36
HTh74 ATC 0.21 43
HTh83 ATC 0.23 32
8305 ATC 2.16 30
8505 ATC 0.16 37
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Statistical analysis was performed by means of the un-
paired Student’s t-test. P-values <0.05 were considered
as statistically significant. For the statistical analysis the
Soft Max® pro software (Molecular Devices) and SPSS
Statistics (IBM Inc, Armonk, NY, USA) were utilized.
Results
GX15-070 decreased viability of thyroid carcinoma cell lines
To investigate the effect of a GX15-070 treatment on
the viability of thyroid carcinoma cells that had been de-
rived from different histological subtypes, we treated 17
cell lines from anaplastic, papillary, and follicular thyroid
carcinoma with GX15-070 or vehicle for 48 h and
assessed the percentage of viable cells compared to con-
trols. GX15-070 treatment decreased the number of cells
in all 17 thyroid carcinoma cell lines analyzed, although
to a variable degree (Table 1). In vitro proliferation assay
data revealed IC50 values in a wide range of concentra-
tion (0.048 to 3.25 μM). The lowest IC50 values of
<0.1 μM were found in follicular FTC133, FTC236, and
FTC238 cells, papillary BHT101 cells and anaplastic
C643 and HTh7 cells. FTC238 and C643 cells were the
most sensitive cell lines (IC50 of 0.048 and 0.049 μM;
Table 1). High IC50 values (>1 μM) were determined in
follicular RO82W cells, papillary K1 cells, and anaplastic
8305 cells. Papillary K1 cells depicted the highest IC50
value of 3.25 μM (Table 1). Follicular ML1 and TT2609
cells, papillary B-CPAP and TPC1 as well as anaplastic
SW1736, HTh74, HTh83, and 8505 cells had IC50
values in the medium range between 0.1 and 1.0 μM
(Table 1). As examples, results for RO82W, TT2609,
FTC238, C643, and SW1736 cells are shown in Fig. 1.
Overall, the GX15-070 treatment decreased the quantity
of viable cells in all 17 thyroid carcinoma cell lines ex-
amined. The IC50 values for GX15-070 treatment
ranged between 0.048 and 3.25 μM, but no correlation
between histological origin of cell lines and sensitivity
towards GX15-070 was obvious. There also was no cor-
relation between the doubling time of cell lines (Table 1)
and sensitivity towards GX15-070 since in the group of
the fastest growing cells (FTC238, TPC-1 and 8305), two
cell lines (FTC238 and TPC-1) had low IC50 values of
0.048 and 0.21 μM, while 8305 cells depict a high IC50
value (2.16 μM; Table 1). Furthermore, ML1 cells which
had the longest doubling time of 68 h, showed an IC50
value in the middle range of 0.16 μM (Table 1).
Expression of BCL-2 family members
We analyzed protein expression profiles of some BCL-2
family members in all cell lines, since there was no obvi-
ous correlation between the sensitivity of the different
cell lines against GX15-070 and the thyroid carcinoma
subtype from which they had been derived. Results aredepicted in Fig. 2 and related to the IC50 values of cells
with GX15-070 as shown in Table 1. The cell lines
showed variable expression levels of proteins of the
BCL-2 family. The expression of the pro-apoptotic pro-
tein BAK was relatively consistent in different cell lines
with FTC236 and HTh83 showing a slightly higher ex-
pression than the other cells (Fig. 2). An expression of
BAX was not detectable in sensitive FTC238 cells (fol-
licular origin) and sensitive C643 cells (anaplastic ori-
gin). In intermediate BHT101 (papillary) and 8505
(anaplastic) cells as well as in insensitive 8305 cells (ana-
plastic origin) BAX expression was weak.
BCL-2 expression was the highest in the GX15-070-
sensitive cell lines FTC133, C643, and HTh7, the inter-
mediate cell lines TT2609, B-CPAP and HTh74, and in
the insensitive cell line RO82W (Fig. 2). No or very weak
BCL-2 expression was found in the intermediate cell
lines ML1, TPC1, HTh83, and the insensitive cell line
8305 (Fig. 2). BCL-xL expression was strong in the
GX15-070 sensitive cell line FTC236, the intermediate
cell lines ML1, B-CPAP, TPC1, SW1736, HTh74, HTh83
and 8505 as well as in the insensitive K1 cell line (Fig. 2).
The expression of MCL-1 was more consistent among
cell lines with the sensitive FTC238 and C643 cells, the
intermediate TPC1 cells, and the GX15-070 insensitive
cell line 8305 exhibiting the lowest MCL-1 expression
(Fig. 2). With respect to the histological origin, there
again was no obvious correlation of expression of the
anti-apoptotic proteins BCL-2, BCL-xL and MCL-1 with
GX15070 (µM)



















Fig. 1 Decreased viability of thyroid carcinoma cells after incubation with GX15-070. Cells were cultured with increasing concentrations of GX15-070 or
vehicle control for 48 h and viability was assessed by MTT assay. Values are reported as percent of vehicle control ± standard deviation. Values represent
mean values of eight-fold determinations of a representative experiment. IC50 values for all cell lines examined are shown in Table 1
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mary, we found no correlation between the GX15-070
sensitivity and the expression of single proteins of the
BCL-2-family or the expression of pro- and anti-
apoptotic BCL-2 family proteins.
Cell cycle analyses after GX15-070 exposure
Cell cycle analyses and the following experiments to deter-
mine the kind of cell death caused by GX15-070 were per-




























































































Fig. 2 Expression of proteins of the BCL-2-family in various thyroid carcinoma
incubation from Table 1 are shown. Equal protein loading was controlled byML1 (follicular), BHT101 (papillary), SW1736 (anaplastic),
HTh7 (anaplastic), and C643 (anaplastic). SW1736 anaplas-
tic cells were shown to be derived from a tumor that origi-
nated from a papillary thyroid carcinoma due to a
BRAFV600E mutation [47] and all six cell lines chosen had
IC50 values around 0.1 μM. Cell cycle analyses after 24 h
treatment with 0.1 μM GX15-070 showed a significant in-
crease of cells in the subG1 fraction in all cell lines ana-
lyzed, pointing to cell death and DNA fragmentation which












































































cells. In addition to the cell line denotations, IC50 values for GX15-070
in-gel protein staining (see “Methods”)
Table 2 Distribution of cell cycle phases in vehicle-treated thyroid carcinoma cells and cells treated for 24 h with 0.1 μM GX15-070
Cell line Stimulation % subG1 % G1 % G2/M % S
FTC236 (FTC)
unstimulated 0.3 ± 0.04 36.7 ± 2.4 17.0 ± 1.1 46.3 ± 3.1
24 h GX15-070 9.9 ± 2.4 * 81.9 ± 5.3 * 12.2 ± 1.7 * 6.0 ± 0.9 *
ML1 (FTC)
unstimulated 1.2 ± 0.3 39.4 ± 1.7 28.5 ± 1.5 32.1 ± 1.8
24 h GX15-070 34.8 ± 3.5 * 82.2 ± 5.4 * 14.3 ± 0.9 * 3.5 ± 0.4 *
BHT101 (PTC)
unstimulated 3.7 ± 0.6 52.5 ± 3.9 16.3 ± 1.1 31.3 ± 2.2
24 h GX15-070 27.9 ± 3.0 * 76.1 ± 5.4 * 15.4 ± 1.4 8.6 ± 1.0 *
SW1736 (ATC)
unstimulated 2.4 ± 0.2 35.9 ± 1.7 24.3 ± 2.0 39.8 ± 2.5
24 h GX15-070 9.3 ± 1.3 * 77.5 ± 5.5 * 11.8 ± 0.9 * 10.8 ± 1.1 *
C643 (ATC)
unstimulated 0.7 ± 0.1 54.5 ± 4.2 13.9 ± 0.9 38.6 ± 2.7
24 h GX15-070 21.7 ± 2.7 * 75.6 ± 5.8 * 10.4 ± 1.2 * 14.0 ± 0.9 *
HTh7 (ATC)
unstimulated 1.1±0.2 55.5 ± 3.9 11.3 ± 0.9 33.2 ± 1.8
24 h GX15-070 4.1 ± 0.3 * 80.0 ± 5.7 * 3.9 ± 0.2 * 16.1 ± 1.0 *
Values for G1-, G2/M-, and S-phases are determined for the living cells that were not included in the sub-G1-peak. * indicates significant changes
(p < 0.05, Student’s t-test)
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est in GX15-070-treated ML1 follicular cells (34.8 %)
followed by papillary BHT101 (27.9 %) and anaplastic C643
cells (21.7 %). The lowest value for the percentage of cells
in subG1 peak after GX15-070 treatment was achieved in
anaplastic HTh7 cells (4.1 %), while follicular FTC236 and
anaplastic SW1736 cells exhibited medium values (9.9 %
and 9.3 %; Table 2). The remaining living cells from all six
cell lines depicted a significant increase in the percentage of
cells in the G1-phase of the cell cycle with 75.6 % to 82.2 %
of all living cells resting in G1-phase (Table 2). After the
GX15-070 treatment, the percentage of cells in the G2/S-
phase and the M-phase of the cell cycle was diminished in
all cell lines examined (Table 2).
Analysis of cell death in GX15-070 treated cells
Cell death analyses were performed in FTC236, ML1,
BHT101, SW1736, HTh7, and C643 cells to evaluate if
GX15-070-treated thyroid carcinoma cells are growth-
inhibited or actively undergo cell death. Furthermore,
these analyses should elucidate the kind of cell death in
GX15-070-treated thyroid carcinoma cells.
Caspase 3 and 7 measurements were performed to in-
vestigate possible apoptotic cell death mechanisms after
the GX15-070 treatment. As shown in Fig. 4a, caspase ac-
tivities were significantly elevated after 6, 16 and 24 h of
GX15-070 treatment in all six thyroid carcinoma cell lines
examined with the highest values after 24 h. ML1 and
C643 cells exhibited the highest increase (253 % and
245 % of control after 24 h), while in FTC236, BHT101,
SW1736, and HTh7 cells, the increase in caspase 3/7 ac-
tivities were in the same range (144 to 184 % of untreated
control after 24 h; Fig. 4a). Moreover, a specific ELISA
analysis in GX15-070-treated cells detected a significantincrease in cleaved caspase 3 as a sign of an activated cas-
pase after 6, 16 and 24 h, while after 2 h no significant in-
crease was seen (Fig. 4b). The increase in cleaved caspase
3 after the GX15-070 treatment was of the same magni-
tude in all six cell lines (146 % to 223 % of control after
6 h, 170 % to 261 % of control after 16 h and 186 % to
272 % of unstimulated control after 24 h; Fig. 4b). LDH
activity in supernatants of vehicle-stimulated and GX15-
070-treated cells was determined to examine the release
of this enzyme that would occur because of a disruption
of cell membranes by necrosis or secondarily to other
kinds of cell death. While after 2 h no significant increase
was seen, after 6 h a small but significant elevation of
LDH was depicted only by ML1, BHT101 and C643 cells,
while all six cell lines examined depicted a significant ele-
vation of LDH content in medium after 16 and 24 h of in-
cubation with 0.1 μM GX15-070 (Fig. 4c). The late LDH
release in all cells after GX15-070 treatment pointed to a
delayed cell disruption after the GX15-070 treatment
which may be, at least in part, due to secondary necrosis.
Taken together, an increase in caspase activation after
GX15-070 treatment together with the DNA fragmenta-
tion depicted as SubG1 peak in cell cycle analyses and
the delayed LDH release pointed to an activation of the
apoptosis machinery in treated cells. To analyze the sig-
nificance of activated caspases in cell death induction,
we co-incubated the cells with 0.1 μM GX15-070 and
1.0 μM Q-VD-OPh, a pan-caspase inhibitor and per-
formed MTT viability assays (Fig. 5). Incubation with
GX15-070 alone resulted in the expected decrease in cell
viability, while incubation with Q-VD-OPh alone had no
significant effect. Combination of both substances
depicted the effect of a GX15-070 incubation alone indi-



















Fig. 3 Cell cycle changes in ML1 and C643 cells after incubation with 0.1 μM GX15-070 for 24 h. Cell cycle analysis was conducted using FACS, results
are shown as examples. Besides the increase in SubG1 peak, in the remaining living cells an increase in the percentage of cells in G1 phase and a
decrease in the percentage of cells in G2/M phase and S phase were observed. Values for all cell lines examined are depicted in Table 2
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examined. As a positive control for Q-VD-OPh action,
we co-incubated Jurkat cells with 2.5 μM staurosporine
which is known to induce apoptosis in these cells [46]
and 1.0 μM Q-VD-OPh and measured caspase 3 and 7
activity and cleaved caspase 3 fragments. Caspase 3 and
7 activity was diminished from 1059 ± 178 % (stauros-
porine alone) to 128 ± 18 % (staurosporine plus Q-VD-
OPh) of control, while cleaved caspase 3 fragments were
diminished from 1371 ± 176 % (staurosporine) to 141 ±
23 % (staurosporine plus Q-VD-OPh).
Furthermore, we used western blot analyses to exam-
ine the LC3 conversion as a marker of autophagic cell
death in the six cell lines after the GX15-070 treatment.
All cells examined in response to the GX15-070 treat-
ment showed a conversion of the 16 KDa LC3-I isoform
to the 14 kDa LC3-II isoform within 4 h (Fig. 6). These
results point to an involvement of autophagic processes
in cell death execution by GX15-070 in thyroid carcin-
oma cells.
In addition to biochemical analyses of treated cell pop-
ulations, ultrastructural changes in thyroid carcinoma
cells treated with GX15-070 were investigated to see
morphological alterations of cell organelles and com-
partments. Only in a small portion of cells (<1 % of ana-
lyzed cells in all cell lines) did we see nuclear changes
characteristic for apoptotic cell death. Instead, after 16and 24 h we noted several other characteristic ultra-
structural changes in cells treated with GX15-070: One
change was swelling of mitochondria combined with loss
of cristae (Fig. 7b, e, f ). We observed wide fields of vacu-
oles probably originating from altered Golgi apparatuses
(Fig. 7d) and dilatation of rough endoplasmic reticulum
(rER) with formation of reticular rER clusters in cells of
all cell lines (Fig. 7b, c) We also noted blebbing and par-
tial destruction of the nuclear membrane in cells of all
cell lines analyzed after GX15-070 treatment (Fig. 7d, f ).
Interestingly, in some cells we observed an association
of the nuclear membrane with membranes of extremely
dilatated rER (Fig. 7c). Moreover, all cell lines contained
cells exhibiting lamellar bodies after GX15-070 treat-
ment (Fig. 7f ). After 48 h of GX15-070 treatment, in
cells from all cell lines examined, we observed a second-
ary necrosis with collapse of plasma membrane and or-
ganelles and spillage of cell content (not shown). In view
of all ultrastructural changes observed we conclude that
GX15-070 treatment caused a characteristic damage in
thyroid carcinoma cells that was not consistent with any
typical form of cell death and which also affected mito-
chondria and other cell organelles.
Discussion
In this study we showed the efficacy of the BH3 mimetic
drug and pan-BCL-2 antagonist GX15-070 for cell death
ab
c
Fig. 4 Increased activity of caspase 3 and 7 (a), increase in the concentration of cleaved caspase 3 fragments as a sign of progressing caspase activity (b) and
increased LDH-release into the cell culture medium (c) after treatment with 0.1 μM GX15-070 for 2, 6, 16 and 24 h in different thyroid carcinoma cell lines.
Values were determined by Apo-One assay, an ELISA specific for caspase 3 fragments and CytoTox-assay and are depicted as percent of vehicle-treated
control. Data represent mean values of eight-fold determinations ± standard deviation; * indicates significant increase (p < 0.05, Student’s t-test)
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Fig. 5 Viability of thyroid carcinoma cells after incubation with 1.0 μM Q-VD-OPh alone, 0.1 μM GX15-070 alone or a combination of both for
48 h. The viability was assessed by MTT assay. Values are reported as percentage of vehicle-treated control ± standard deviation and represent the
mean of eight-fold determinations; * indicates significant decrease (p < 0.05, Student’s t-test)
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logical origins. The dying cells underwent a non-classical
way of cell death.
Since the evasion of cell death is one of the characteris-
tics of cancer cells and contributes significantly to tumor
progression and resistance to treatment, the pharmaco-
logical manipulation of apoptosis-related pathways is a
promising strategy for cancer treatment [12]. The resist-
ance to cell death by apoptosis can be mediated through
an overexpression of anti-apoptotic proteins of the BCL-2
family, whose expression often correlates with drug resist-
ance [48, 49]. BH3 mimetics are a class of low-molecular
weight substances that manipulate the balance of pro- and
anti-apoptotic mechanisms by inhibiting BCL-2 proteins.
GX15-070 is one of these BH3 mimetic drugs and has
already been investigated in some pre-clinical models of
various tumors. It has shown antitumor activity e.g. in
leukemia, lymphoma, and lung cancer cells [36, 37, 50–52].
Furthermore, GX15-070 has recently shown anti-tumor
effects in two mouse cell lines derived from mice
with thyroid-specific activation of Kras and deletion of
p53, which develop PTC and subsequently poorly differ-
entiated thyroid carcinoma and ATC and one human
ATC cell line [53].
In our experiments, GX15-070 showed inhibitory ef-
fects on the numbers of viable cells in all 17 human thy-
roid carcinoma cell lines examined, although to a
variable degree as measured per IC50 value (Fig. 1 and
Table 1). The IC50 values for most thyroid carcinomacell lines (13 of 17) investigated were below 0.50 μM
and thus lower than the values that had been seen in
most other human cell models (lung cancer cells: 1-
2 μM [37]; CLL cells: 1.7 μM at 48 h [54]) which may, at
least in part, also be due to different culture conditions
and cell culture media. In contrast, Champa et al. [53]
described IC50 values in the low nanomolar range for
inhibition of two mouse cell lines derived from thyroid
tumors. We observed no relationship between the ex-
pression of the proteins of the BCL-2 family and the
sensitivity against GX15-070. Furthermore, no correl-
ation was found neither between the GX15-070 sensitiv-
ity and the thyroid carcinoma subtype from which the
cell lines had been derived nor the doubling time of cell
lines. With respect to the putative mechanism of the cell
death induction after GX15-070 stimulation, an expres-
sion of BAK and BAX would be essential for apoptosis
induction. This is supported by the work of Nguyen
et al. [35], who demonstrated the failure of GX15-070 in
apoptosis induction in mouse kidney cells deficient for
BAX and BAK. In BAK/BAX double knockout mouse
embryonic fibroblast cell lines GX15-070-induced cell
death was prevented [55]. Konopleva et al. [52] showed
the dependency on BAK and BAX expression for a cell
death induced by GX15-070 in AML cells. Furthermore,
in cholangiocarcinoma cells, GX15-070 was shown to be
a direct activator of BAX [56]. In contrast, in our cells
no correlation between expression of these two pro-



























Fig. 6 Conversion of LC3-I (16 kDa) to LC3-II (14 kDa) after
GX15-070-treatment indicating autophagic processes. Western
blot analyses of vehicle-treated and GX15-070-treated thyroid carcinoma
cell lines using LC3A/B antibody are shown. Equal protein loading was
controlled by in-gel protein staining (see “Methods”)
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expression in FTC238 cells and C643 cells which were
both sensitive to GX15-070 (IC50 values of 0.048 μM
and 0.049 μM) and a high BAX expression in insensitive
RO82W and K1 cells (Fig. 2). These results correspond
to those of McCoy et al. [57] who showed that the loss of
viability by GX15-070 treatment was not prevented in BAK/
BAX knockout mouse embryonic fibroblasts and also to the
data of Brem et al. [58] who reported on cell death induction
by GX15-070 in lymphoma cells regardless of baseline BAK
and BAX levels. The low IC50 values observed in most of
our thyroid carcinoma cell lines as well as the lack of correl-
ation of the GX15-070 sensitivity with expression of BAX
and BAK and other proteins of the BCL-2 family provided
first hints on possible other mechanisms of molecular action
of GX15-070 in thyroid carcinoma cells in addition to those
of BH3 mimetic activity as also discussed by others [57, 58].
Our biochemical and morphological data in thyroid car-
cinoma cells treated with GX15-070 support a mixed kind
of cell death with biochemical signs of apoptosis and necro-
sis as well as autophagic cell death. While an increased ac-
tivity of caspases, which is typical for apoptosis, was seen in
all six cell lines examined, the significance of caspase activa-
tion for loss of viability in GX15-070-treated thyroidcarcinoma cells was low because combined treatment with
GX15-070 and the pan-caspase inhibitor Q-VD-OPh did
not prevent cell death. These results again fit with those of
McCoy et al. [57] who described apoptotic and autophagic
cell death induction by GX15-070 in non-small cell lung
cancer cells. Furthermore, cell death occurred in conditions
with complete inhibition of apoptosis pointing to the rele-
vance of death-inducing pathways other than apoptosis
[57]. These authors reported GX15-070 dependent
autophagy-induction in parallel with further death inducing
mechanisms like vacuolation [57]. Similar findings were
also reported by other authors: In leukemia cells, GX15-
070 was found to induce both apoptosis and autophagy
[59, 60] which in ALL cells are independently regulated
[59]. Bonapace et al. reported on GX15-070-induced
autophagy-dependent necroptosis in apoptosis-deficient,
drug-resistant childhood ALL cells [61]. Moreover, Basit
et al. found GX15-070-induced necroptosis and autophagy
in RMS rhabdomyosarcoma cells without signs of apoptosis
[62]. These authors reported on GX15-070-stimulated as-
sembly of the necrosome on autophagosomal membranes
which is interpreted as a connection between GX15-070-
stimulated autophagy and necroptosis [62]. Furthermore,
GX15-070-induced autophagy may contribute significantly
to cell death since GX15-070 treatment was also found to
inhibit cathepsin D- and cathepsin L expression which in
turn limits the ability of the treated cell to re-use degraded
material and thus enables cell death [63]. The results in our
cell lines fit very well with these findings. An LDH release
typical for cell death by necrosis was found as well in our
GX15-070-treated thyroid carcinoma cells. It may be due
to necroptosis or secondary necrosis since it was much
stronger after 16 and 24 h than after 2 and 6 h. Further-
more, LC3 cleavage and morphological changes indicating
autophagic mechanisms were demonstrated in parallel in
all thyroid carcinoma cell lines. These findings are in line
with literature reports [57, 61, 62]. Cell cycle analyses in
addition pointed to DNA fragmentation in GX15-070-
treated cells as well as growth inhibition by cell cycle arrest
in the G1-phase. These results are in accordance with data
from the literature that cell death in vivo often is not in ac-
cordance with a single cell death mode, but comprises a
mix of apoptotic, necrotic and autophagic elements. All
kinds of cell death can occur independently of each other
or simultaneously resulting in a combined cell death
phenotype [64, 65].
Furthermore, electron microscopy revealed ultrastruc-
tural signs of atypical cell death with swelling of mito-
chondria and loss of cristae before cell death as well as
disintegration of nuclear membrane, partly extreme dila-
tation of rER with formation of rER clusters, as well as
the formation of vacuoles in the majority of cells, and
the occurrence of lamellar bodies and autophagosomes.












Fig. 7 Electron microscopic images of cell death in thyroid carcinoma cells. Untreated SW1736 cells (a) with intact membranes, normal organelles, and
morphology, (b) SW1736, (c) HTh7, (d) TPC1, (e) TPC1, and (f) BHT101 cells treated for 16 (c, d, e) or 24 h (b, f) with 0.1 μM GX15-070 as examples for swelling
of mitochondria with loss of cristae (white arrows), blebbing of nuclear membrane (black arrows), extreme dilatation of rER with formation of reticular rER
clusters (black asterisks), association of the nuclear membrane with membranes of dilatated rER black arrowhead), vacuoles probably originating from Golgi
apparatuses (white arrowheads) as well as lamellar bodies and autophagosomes (white asterisks)
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late LDH release depicted through biochemical methods.
Similar changes, at least in part, have already described by
Vogler et al. [66] and McCoy and coworkers [57]. In non-
small cell lung cancer cells, GX15-070 induced a cytoplas-
mic vacuolation and vesicle formation in the cytoplasm[57]. Vogler et al. [66] described morphological changes in
GX15-070 treated CLL cells similar to those seen in thy-
roid carcinoma cells at least in mitochondria. These au-
thors discuss the death induction of GX15-070 by severe
mitochondrial damage. This may compromise the ability
of the treated cells to generate ATP by oxidative
Broecker-Preuss et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:69 Page 13 of 14phosphorylation and in turn impair the ability of the cells
to undergo the ATP-dependent process of apoptosis [66].
In our cells, the nuclear membrane was identified as an
additional target of GX15-070, maybe involving lamins
that were recently identified to be involved in nuclear
blebbing [67]. Furthermore, we observed a disintegration
of some Golgi apparatuses and generation of partly ex-
tremely dilatated rER networks some of which were in
conjunction with the nuclear membrane. This prolifera-
tion and cluster formation of rER pointed to additional
cellular targets perhaps in the context with membrane for-
mation and regulation. These results match those of
Albershardt et al. [68] who reported on an induction of
the endoplasmic stress response by GX15-070 and other
BH3 mimetics. One could speculate that these cellular
changes may facilitate death induction by alternative and
atypical pathways.
Although GX15-070 was shown to inhibit the binding
of a BH3 peptide to recombinant fragments of all anti-
apoptotic proteins of the BCL-2 family with Ki values of
1-7 μM [69], our results and those reported by others
argue for additional intracellular targets of GX15-070. The
low IC50 values for GX15-070 that we observed in most
of our thyroid carcinoma cells hint at so far unknown cel-
lular target proteins that have a higher affinity to GX15-
070 than BCL-2 proteins. Furthermore, one would expect
that BCL-2 antagonists that bind specifically to anti-
apoptotic BCL-2 proteins do not lead to a mixed form of
cell death but may cause apoptotic cell death.Conclusions
GX15-070 was found to efficiently kill dedifferentiated
thyroid carcinoma cells although the exact kind of cell
death remains to be elucidated. Our findings confirm the
results of others [57, 66] that GX15-070 is not specific for
proteins of the BCL-2 family and induces a mixed kind of
cell death with signs of apoptosis, autophagy and necrosis
[57–63, 66]. Moreover, GX15-070 targets additional intra-
cellular structures and organelles like mitochondria and
intracellular membranes and induces vacuole formation.
GX15-070 and related compounds thus may be valuable
as a new therapeutic option for dedifferentiated thyroid
cancer, irrespective of the exact target molecules and the
kind of cell death it induces.
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